Clinical trial NCT02094612: Effectiveness of the Quotient® ADHD Assessment in a System of Care
Official title: Effectiveness of the Quotient® ADHD Assessment in a System of Care
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Attention Deficit and Disruptive Behavior Disorders
Attention Deficit Disorder With Hyperactivity
Keywords: Attention Deficit and Disruptive Behavior Disorders
Attention Deficit Disorder with Hyperactivity
Pediatrics
Patient Outcome Assessment
Lead sponsor: Kaiser Permanente
Sponsor class: OTHER
Collaborators: name: Pearson/Clinical Assessment
First posted: 2014-03-24
Enrollment: 207
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The study goal is to examine whether the use of an objective computerized neuroassessment (the Quotient System) for Attention-Deficit/Hyperactivity Disorder (ADHD) is related to improved outcomes among pediatric patients being assessed and treated for ADHD.

Detailed description: This study is a randomized, controlled trial using a 2-phase data collection. The first phase is the initial assessment for ADHD and includes all patients eligible to be assessed for ADHD as determined by their clinician in the course of usual care. The baseline measurements will be used to compare groups at baseline, and also for longitudinal analyses of medication management. Patients are randomized at this point. Patients in both treatment arms who then receive an ADHD diagnosis and who start medication for ADHD will be eligible for the second phase of the study: three follow-up assessments over six months. Patients who do not have an ADHD diagnosis will not continue in the study, and will be treated by their clinician as usual.

Eligibility criteria: Inclusion Criteria:

* All patients within the specified age range who are English speaking and who are presenting for ADHD assessment are eligible. An additional criterion is consent to be randomized.

Exclusion Criteria:

* Non English speaking
* Refusal to participate

Primary outcomes:
measure: Number of Participants With 25% Reduction in SNAP Scores
timeFrame: One month, 3 month and six month follow ups
Secondary outcomes:
measure: ADHD Symptomatology
timeFrame: 6 months post baseline
measure: Academic Performance
timeFrame: Baseline and Six Months
measure: Persistence in Care
timeFrame: Baseline to Six Months
measure: Medication Adherence
timeFrame: Baseline to six months
measure: Satisfaction With Care
timeFrame: Six months
measure: Other Health Services Use
timeFrame: Baseline to six months
Other outcomes:
Locations:
city: Folsom
country: United States
facility: Kaiser Permanente, Folsom
state: California
city: Roseville
country: United States
facility: Kaiser Permanente, Roseville
state: California
city: Walnut Creek
country: United States
facility: Kaiser Permanente, Walnut Creek Medical Center
state: California
Study officials:
affiliation: Kaiser Permanente
name: Cynthia I Campbell, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chinchilli VM, Fisher L, Craig TJ. Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge. J Allergy Clin Immunol. 2005 Mar;115(3):592-7. doi: 10.1016/j.jaci.2005.01.008.
citation: Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics. 2000 May;105(5):1158-70. doi: 10.1542/peds.105.5.1158.
citation: Foy JM, Earls MF. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder. Pediatrics. 2005 Jan;115(1):e97-104. doi: 10.1542/peds.2004-0953.
citation: Herrerias CT, Perrin JM, Stein MT. The child with ADHD: using the AAP Clinical Practice Guideline. American Academy of Pediatrics. Am Fam Physician. 2001 May 1;63(9):1803-10.
citation: Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005 Sep;162(9):1628-36. doi: 10.1176/appi.ajp.162.9.1628.
citation: Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986 Sep;42(3):507-19.
citation: Langberg JM, Froehlich TE, Loren RE, Martin JE, Epstein JN. Assessing children with ADHD in primary care settings. Expert Rev Neurother. 2008 Apr;8(4):627-41. doi: 10.1586/14737175.8.4.627.
citation: Leslie LK, Weckerly J, Plemmons D, Landsverk J, Eastman S. Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings. Pediatrics. 2004 Jul;114(1):129-40. doi: 10.1542/peds.114.1.129.
citation: Leslie LK, Wolraich ML. ADHD service use patterns in youth. J Pediatr Psychol. 2007 Jul;32(6):695-710. doi: 10.1093/jpepsy/jsm023. Epub 2007 Jun 7.
citation: Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012 Sep 4;10:99. doi: 10.1186/1741-7015-10-99.
citation: Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007 Jul;32(6):711-27. doi: 10.1093/jpepsy/jsm022. Epub 2007 Jun 7.
citation: Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983 Jun;39(2):499-503.
citation: Xie H, McHugo G, Drake R, Sengupta A. Using discrete-time survival analysis to examine patterns of remission from substance use disorder among persons with severe mental illness. Ment Health Serv Res. 2003 Mar;5(1):55-64. doi: 10.1023/a:1021759509176.